SAN FRANCISCO, Calif., June 26, 2026
Epicrispr Biotechnologies announced encouraging interim Phase 1/2 clinical trial results for EPI-321, its investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD), reporting the first clinical evidence of increased lean muscle volume in patients treated for the progressive neuromuscular disease. The findings represent a potential breakthrough in FSHD, where patients typically experience continuous muscle loss and currently have no approved disease-modifying therapies. As of the May 12, 2026 data cutoff, nine patients had been treated across two dose cohorts, with no serious adverse events reported. Among the first three evaluable patients receiving the target dose, all demonstrated measurable gains in lean muscle volume after six months, averaging approximately 370 mL (0.8 pounds) of additional muscle mass, with some individual muscles increasing by as much as 15%. EPI-321 is designed to silence DUX4, the genetic driver of FSHD, through the company’s proprietary Gene Expression Modulation System (GEMS) platform, aiming to provide durable suppression of disease-causing gene activity without altering the underlying DNA.
EPI-321 Demonstrates Biological Activity and Muscle Improvement
The interim data suggest that EPI-321 may be capable of addressing the underlying biology of FSHD rather than only managing symptoms. According to the company, increases in lean muscle volume observed through advanced MRI analysis were supported by favorable reductions in a circulating cell-free DNA biomarker associated with DUX4 pathway activity, providing additional evidence of target engagement. These biomarker findings were also consistent with previously reported improvements in muscle strength and functional assessments observed at the three-month evaluation. Researchers emphasized that muscle gain is particularly notable because previous FSHD clinical studies, including late-stage trials, have generally documented progressive muscle deterioration over time. Investigators believe the combination of imaging, biomarker, and functional improvements strengthens confidence that EPI-321 has the potential to become a disease-modifying therapy capable of slowing or altering disease progression.
Safety Profile Supports Continued Clinical Development
The ongoing first-in-human study continues to demonstrate a positive safety profile, with no serious adverse events reported across either dose cohort. Six participants received a single intravenous infusion at the target dose of 2×10¹³ vg/kg, while three additional patients received a higher dose of 4×10¹³ vg/kg. MRI assessments were conducted in collaboration with Springbok Analytics, whose AI-powered imaging platform enabled detailed measurement of lean muscle volume across as many as 140 individual muscles throughout the body. According to investigators, the consistency of muscle growth observed across all evaluable patients is encouraging, particularly in a disease where muscle degeneration is expected. Clinical experts cautioned that the results remain preliminary due to the limited number of patients evaluated but noted that the findings justify continued investigation in larger patient populations.
Advertisement
Future Development Plans for EPI-321
Epicrispr plans to continue enrollment and follow-up in the ongoing Phase 1/2 clinical trial (NCT06907875), which is evaluating the safety, tolerability, biological activity, and preliminary efficacy of EPI-321 in adults with FSHD. The company expects to present additional clinical results at the World Muscle Society Annual Congress in September 2026, while completion of the primary portion of the study is anticipated by mid-2027. If future data continue to demonstrate durable muscle preservation and functional improvements, EPI-321 could emerge as the first investigational therapy designed to silence DUX4 while offering a novel epigenetic approach for treating FSHD. The program also highlights the growing potential of gene-modulating therapies to address the genetic causes of rare neuromuscular disorders through long-lasting regulation of disease-driving genes.
Source: Epicrispr Biotechnologies press release
